Despite the COVID-19 pandemic, there has been considerable activity in the clinical development of novel and improved drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) during 2020. The agents that were investigated can be divided into “symptomatic” (alleviating the features of the condition) and “disease modifying” (attempting to address the underlying biology of PD) treatments, ST and DMT respectively, with further categorisation possible based on mechanism of action and class of therapy.
Parkinson’s Disease Drug Therapies in the... - Cure Parkinson's
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
Thanks Farooqji
Here is a link to the master list of treatments being trialed:
There is also a PNT article about the document.
Clinical Trials of Parkinson’s Therapies Robust Despite COVID-19
Far more relevant to analyze the Phase III trials and their results.
Not what you're looking for?
You may also like...
Parkinson’s disease stem cell therapy research update
stem cells for Parkinson’s....
Light Therapy for Parkinson’s Disease
light therapy information together in one place:...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
option before: Electroconvulsive Therapy Intervention for Parkinson’s Disease...
Light Therapy Clinical Trial
symptoms of Parkinson's disease.
This trial will be of great interest to people with Parkinson's,...
Clinical Trial Update
hase-2-for-a-mesenchymal-stem-cell-therapy-for-parkinsons-disease.-looks-promising-any-thoughts